Assessment of viral inactivation during pH 3.3 pepsin digestion and caprylic acid treatment of antivenoms

Thierry Burnouf, Fokke Terpstra, George Habib, Salwa Seddik

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Antivenoms are manufactured by the fractionation of animal plasma which may possibly be contaminated by infectious agents pathogenic to humans. This study was carried out to determine whether pre-existing antivenom production steps, as carried out by EgyVac in Egypt, may reduce viral risks. Two typical manufacturing steps were studied by performing down-scaled viral inactivation experiments: (a) a pH 3.3 pepsin digestion of diluted plasma at 30 °C for 1 h, and (b) a caprylic acid treatment of a purified F(ab′)2 fragment fraction at 18 °C for 1 h. Three lipid-enveloped (LE) viruses [bovine viral diarrhoea virus (BVDV), pseudorabies virus (PRV), and vesicular stomatitis virus (VSV)] and one non-lipid-enveloped (NLE) virus [encephalomyocarditis virus (EMC)] were used as models. Kinetics of inactivation was determined by taking samples at 3 time-points during the treatments. The pH 3.3 pepsin digestion resulted in complete clearance of PRV (>7.0 log10) and in almost complete reduction of VSV (>4.5 but ≤6.4 log10), and in a limited inactivation of BVDV (1.7 log10). EMC inactivation was ≥2.5 but ≤5.7 log10. The caprylic acid treatment resulted in complete inactivation of the 3 LE viruses tested: BVDV (>6.6 log10), PRV (>6.6 log10), and VSV (>7.0 log10). For EMC no significant reduction was obtained (0.7 log10). Cumulative reduction was >13.6, >11.5, >8.3 and ≥2.5 for PRV, VSV, BVDV and EMC, respectively. Therefore the current manufacturing processes of at least some animal antisera already include production steps that can ensure robust viral inactivation of LE viruses and moderate inactivation of a NLE virus.

Original languageEnglish
Pages (from-to)329-334
Number of pages6
JournalBiologicals
Volume35
Issue number4
DOIs
Publication statusPublished - Oct 2007
Externally publishedYes

Fingerprint

Virus Inactivation
Antivenins
Pepsin A
Viruses
Digestion
Encephalomyocarditis virus
Bovine Viral Diarrhea Viruses
Suid Herpesvirus 1
Vesicular Stomatitis
Acids
Lipids
octanoic acid
Egypt
Immune Sera
Animals

Keywords

  • Acid pH
  • Antivenom
  • Caprylate
  • Horse
  • Immunoglobulins
  • Plasma
  • Safety
  • Virus

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Infectious Diseases

Cite this

Assessment of viral inactivation during pH 3.3 pepsin digestion and caprylic acid treatment of antivenoms. / Burnouf, Thierry; Terpstra, Fokke; Habib, George; Seddik, Salwa.

In: Biologicals, Vol. 35, No. 4, 10.2007, p. 329-334.

Research output: Contribution to journalArticle

Burnouf, Thierry ; Terpstra, Fokke ; Habib, George ; Seddik, Salwa. / Assessment of viral inactivation during pH 3.3 pepsin digestion and caprylic acid treatment of antivenoms. In: Biologicals. 2007 ; Vol. 35, No. 4. pp. 329-334.
@article{b83e3f2947d94378ae04b2acc63d4e93,
title = "Assessment of viral inactivation during pH 3.3 pepsin digestion and caprylic acid treatment of antivenoms",
abstract = "Antivenoms are manufactured by the fractionation of animal plasma which may possibly be contaminated by infectious agents pathogenic to humans. This study was carried out to determine whether pre-existing antivenom production steps, as carried out by EgyVac in Egypt, may reduce viral risks. Two typical manufacturing steps were studied by performing down-scaled viral inactivation experiments: (a) a pH 3.3 pepsin digestion of diluted plasma at 30 °C for 1 h, and (b) a caprylic acid treatment of a purified F(ab′)2 fragment fraction at 18 °C for 1 h. Three lipid-enveloped (LE) viruses [bovine viral diarrhoea virus (BVDV), pseudorabies virus (PRV), and vesicular stomatitis virus (VSV)] and one non-lipid-enveloped (NLE) virus [encephalomyocarditis virus (EMC)] were used as models. Kinetics of inactivation was determined by taking samples at 3 time-points during the treatments. The pH 3.3 pepsin digestion resulted in complete clearance of PRV (>7.0 log10) and in almost complete reduction of VSV (>4.5 but ≤6.4 log10), and in a limited inactivation of BVDV (1.7 log10). EMC inactivation was ≥2.5 but ≤5.7 log10. The caprylic acid treatment resulted in complete inactivation of the 3 LE viruses tested: BVDV (>6.6 log10), PRV (>6.6 log10), and VSV (>7.0 log10). For EMC no significant reduction was obtained (0.7 log10). Cumulative reduction was >13.6, >11.5, >8.3 and ≥2.5 for PRV, VSV, BVDV and EMC, respectively. Therefore the current manufacturing processes of at least some animal antisera already include production steps that can ensure robust viral inactivation of LE viruses and moderate inactivation of a NLE virus.",
keywords = "Acid pH, Antivenom, Caprylate, Horse, Immunoglobulins, Plasma, Safety, Virus",
author = "Thierry Burnouf and Fokke Terpstra and George Habib and Salwa Seddik",
year = "2007",
month = "10",
doi = "10.1016/j.biologicals.2006.11.003",
language = "English",
volume = "35",
pages = "329--334",
journal = "Biologicals",
issn = "1045-1056",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - Assessment of viral inactivation during pH 3.3 pepsin digestion and caprylic acid treatment of antivenoms

AU - Burnouf, Thierry

AU - Terpstra, Fokke

AU - Habib, George

AU - Seddik, Salwa

PY - 2007/10

Y1 - 2007/10

N2 - Antivenoms are manufactured by the fractionation of animal plasma which may possibly be contaminated by infectious agents pathogenic to humans. This study was carried out to determine whether pre-existing antivenom production steps, as carried out by EgyVac in Egypt, may reduce viral risks. Two typical manufacturing steps were studied by performing down-scaled viral inactivation experiments: (a) a pH 3.3 pepsin digestion of diluted plasma at 30 °C for 1 h, and (b) a caprylic acid treatment of a purified F(ab′)2 fragment fraction at 18 °C for 1 h. Three lipid-enveloped (LE) viruses [bovine viral diarrhoea virus (BVDV), pseudorabies virus (PRV), and vesicular stomatitis virus (VSV)] and one non-lipid-enveloped (NLE) virus [encephalomyocarditis virus (EMC)] were used as models. Kinetics of inactivation was determined by taking samples at 3 time-points during the treatments. The pH 3.3 pepsin digestion resulted in complete clearance of PRV (>7.0 log10) and in almost complete reduction of VSV (>4.5 but ≤6.4 log10), and in a limited inactivation of BVDV (1.7 log10). EMC inactivation was ≥2.5 but ≤5.7 log10. The caprylic acid treatment resulted in complete inactivation of the 3 LE viruses tested: BVDV (>6.6 log10), PRV (>6.6 log10), and VSV (>7.0 log10). For EMC no significant reduction was obtained (0.7 log10). Cumulative reduction was >13.6, >11.5, >8.3 and ≥2.5 for PRV, VSV, BVDV and EMC, respectively. Therefore the current manufacturing processes of at least some animal antisera already include production steps that can ensure robust viral inactivation of LE viruses and moderate inactivation of a NLE virus.

AB - Antivenoms are manufactured by the fractionation of animal plasma which may possibly be contaminated by infectious agents pathogenic to humans. This study was carried out to determine whether pre-existing antivenom production steps, as carried out by EgyVac in Egypt, may reduce viral risks. Two typical manufacturing steps were studied by performing down-scaled viral inactivation experiments: (a) a pH 3.3 pepsin digestion of diluted plasma at 30 °C for 1 h, and (b) a caprylic acid treatment of a purified F(ab′)2 fragment fraction at 18 °C for 1 h. Three lipid-enveloped (LE) viruses [bovine viral diarrhoea virus (BVDV), pseudorabies virus (PRV), and vesicular stomatitis virus (VSV)] and one non-lipid-enveloped (NLE) virus [encephalomyocarditis virus (EMC)] were used as models. Kinetics of inactivation was determined by taking samples at 3 time-points during the treatments. The pH 3.3 pepsin digestion resulted in complete clearance of PRV (>7.0 log10) and in almost complete reduction of VSV (>4.5 but ≤6.4 log10), and in a limited inactivation of BVDV (1.7 log10). EMC inactivation was ≥2.5 but ≤5.7 log10. The caprylic acid treatment resulted in complete inactivation of the 3 LE viruses tested: BVDV (>6.6 log10), PRV (>6.6 log10), and VSV (>7.0 log10). For EMC no significant reduction was obtained (0.7 log10). Cumulative reduction was >13.6, >11.5, >8.3 and ≥2.5 for PRV, VSV, BVDV and EMC, respectively. Therefore the current manufacturing processes of at least some animal antisera already include production steps that can ensure robust viral inactivation of LE viruses and moderate inactivation of a NLE virus.

KW - Acid pH

KW - Antivenom

KW - Caprylate

KW - Horse

KW - Immunoglobulins

KW - Plasma

KW - Safety

KW - Virus

UR - http://www.scopus.com/inward/record.url?scp=35348898600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348898600&partnerID=8YFLogxK

U2 - 10.1016/j.biologicals.2006.11.003

DO - 10.1016/j.biologicals.2006.11.003

M3 - Article

VL - 35

SP - 329

EP - 334

JO - Biologicals

JF - Biologicals

SN - 1045-1056

IS - 4

ER -